[1]Treitman AN, Yarnold PR, Warren J,et al. Emerging incidence of Enterococcus faecium among hospital isolates (1993 to 2002) [J]. J Clin Microbiol, 2005, 43(1): 462-463.
[2]Fisher K, Phillips C. The ecology, epidemiology and virulence ofEnterococcus[J]. Microbiology (Reading), 2009, 155(Pt 6): 1749-1757.
[3]Zhou W, Zhou H, Sun Y,et al. Characterization of clinical enterococci isolates, focusing on the vancomycin-resistant enterococci in a tertiary hospital in China: based on the data from 2013 to 2018[J]. BMC Infect Dis, 2020, 20(1): 356.
[4]Zhou W, Gao S, Xu H,et al. Distribution of the optrA gene in Enterococcus isolates at a tertiary care hospital in China[J]. J Glob Antimicrob Resist, 2019, 17: 180-186.
[5]Zheng JX, Wu Y, Lin ZW,et al. Characteristics of and virulence factors associated with biofilm formation in clinical Enterococcus faecalis isolates in China[J]. Front Microbiol, 2017, 8: 2338.
[6]Chilambi GS, Nordstrom HR, Evans DR,et al. Evolution of vancomycin-resistant Enterococcus faecium during colonization and infection in immunocompromised pediatric patients[J]. Proc Natl Acad Sci USA, 2020, 117(21): 11703-11714.
[7]Clinical and Laboratory Standards Institute.Performance standards for antimicrobial susceptibility testing. 29th ed. CLSI supplement M100 [S]: Wayne, PA: CLSI, 2019.
[8]周万青, 宋熙晶, 生媛, 等. 多中心耐利奈唑胺凝固酶阴性葡萄球菌耐药机制及同源性分析[J]. 临床检验杂志, 2020, 38(1): 29-33.
[9]Zheng JX, Bai B, Lin ZW,et al. Characterization of biofilm formation by Enterococcus faecalis isolates derived from urinary tract infections in China[J]. J Med Microbiol, 2018, 67(1): 60-67.
[10]牛冬梅, 徐红静, 周万青, 等. 血液分离肠球菌毒力基因及生物膜形成相关性分析[J]. 标记免疫分析与临床, 2019, 26(7): 1105-1109.
[11]Zhou W, Niu D, Cao X,et al. Clonal dissemination of linezolid-resistant Staphylococcus capitis with G2603T mutation in domain V of the 23S rRNA and the cfr gene at a tertiary care hospital in China[J]. BMC Infect Dis, 2015, 15: 97.
[12]高硕, 周万青, 朱宏, 等. 利奈唑胺耐药金黄色葡萄球菌耐药机制分析[J]. 临床检验杂志, 2020, 38(8): 613-616.
[13]Antonelli A, D’Andrea MM, Brenciani A,et al. Characterization of poxtA, a novel phenicol-oxazolidinone-tetracycline resistance gene from an MRSA of clinical origin[J]. J Antimicrob Chemother, 2018, 73(7): 1763-1769.
[14]Paganelli FL, Willems RJ, Leavis HL. Optimizing future treatment of enterococcal infections: attacking the biofilm? [J] Trends Microbiol, 2012, 20(1): 40-49.
[15]Thomas VC, Thurlow LR, Boyle D,et al. Regulation of autolysis-dependent extracellular DNA release by Enterococcus faecalis extracellular proteases influences biofilm development[J]. J Bacteriol, 2008, 190(16): 5690-5698.
[16]Van Tyne D, Martin MJ, Gilmore MS. Structure, function, and biology of theEnterococcus faecalis cytolysin[J]. Toxins (Basel), 2013, 5(5):895-911.
[17]Seno Y, Kariyama R, Mitsuhata R, et al. Clinical implications of biofilm formation by Enterococcus faecalis in the urinary tract[J]. Acta Med Okayama, 2005, 59(3):79-87.
[18]朱宏, 高硕, 周辉, 等. 尿路感染中肠球菌耐药性及毒力基因分析[J]. 东南国防医药, 2019, 21(5): 466-469.